Table 1 Clinicopathological characteristics of the patients at the pre-treatment setting
From: Increased blood draws for ultrasensitive ctDNA and CTCs detection in early breast cancer patients
Clinical characteristics | n (%) | |
|---|---|---|
Diagnostic age (years) | ||
<50 | 9 (43%) | |
>50 | 12 (57%) | |
Histological subtype | ||
IDC | 20 (95%) | |
ILC | 1 (5%) | |
Tumor subtype | ||
Luminal | 13 (62%) | |
Triple negative | 7 (33%) | |
HER2-enriched | 1 (5%) | |
Tumor grade | ||
2 | 5 (24%) | |
3 | 16 (76%) | |
TNM | ||
IIA | cT2N0 | 8 (38%) |
IIB | cT2N1 | 6 (29%) |
cT3N0 | 3 (14%) | |
IIIA | ct2N2 | 2 (9%) |
cT3N1 | 1 (5%) | |
IIIB | cT4bN1 | 1 (5%) |
Axillar lymph node | ||
N0 | 12 (57%) | |
N1 | 6 (29%) | |
N2 | 2 (9%) | |
N3 | 1 (5%) | |
Estrogenic receptor | ||
Positive | 13 (62%) | |
Negative | 8 (38%) | |
Progesterone receptor | ||
Positive | 8 (38%) | |
Negative | 13 (62%) | |
HER2 status | ||
Positive | 11 (52%) | |
Negative | 10 (48%) | |
BIRADS category | ||
4/B/C | 6 (29%) | |
5 C | 15 (71%) | |
PCR | ||
Yes | 7 (33%) | |
No | 14 (67%) | |
Clinical relapse | ||
Yes | 3 (14%) | |
No | 18 (86%) | |
